PDF factsheet
      Z

new drug under development in acute heart failure for all type of patients, clinical trials results

beta-blockade continuation versus discontinuation
B-CONVINCED, 2009
NCT00162565).
beta-blockade continuation
versus
discontinuation BB
acutely decompensated heart failure in patients with LVEF below 40% previously receiving stable beta-blocker therapyopen
France
levosimendan versus dobutamine
CASINO, 0
Levosimendan 16 mg/kg þ 0.2 mg/kg/min
versus
Dobutamine (10 mg/kg/min) and placebo
patients withdecompensatedlow-output HF
LIDO, 2002
Levosimendan
versus
Dobutamine
patients with low-output heart failuredouble-blind
Follow-up duration: 24h
SURVIVE, 2007
NCT00348504
Intravenous levosimendan
versus
intravenous dobutamine
patients hospitalized with acute decompensated heart failure who required inotropic supportdouble-blind
Follow-up duration: 180 days
9 countries
levosimendan versus placebo
REVIVE-I, 2003
levosimendan 0.1–0.2 mg/kg/min
versus
placebo
patienst with HF andsymptoms at rest
REVIVE II, 2013
NCT00048425
Intravenous Levosimendan
versus
placebo
patients with decompensated chronic heart failuredouble blind
Follow-up duration: 5 days
RUSSLAN, 2002
Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h
versus
placebo
patients with left ventricular failure complicating acute myocardial infarctiondouble-blind
Follow-up duration: 14 days
nesiritide versus control
NSGET (comparative trial), 2000
nesiritide(0.015 and 0.030 microg/kg/min
versus
usual care
acutely decompensated heart failure requiring invasive monitoring open
Follow-up duration: <5 days
US
nesiritide versus dobutamine
PRECEDENT, 2002
NCT00270400
nesiritide(0.015 or 0.03 microg/kg/min)
versus
Dobutamine (> or =5 microg/kg/min)
Symptomatic, Decompensated CHFopen
nesiritide versus nitroglycerin
VMAC (24h), 2002
NCT00083772
nesiritideinfusion for 24 hours
versus
nitroglycerin
acutely decompensated heart failure requiring hospitalization
nesiritide versus placebo
ASCEND-HF, 2011
NCT00475852
intravenous nesiritide for 24 hours to 7 days on top of standard therapy
versus
matching placebo
Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)double-blind
Follow-up duration: 30 days
North America, Europe, Latin America, Asia-Pacific region
BNP-CARDS, 2007
NCT00186329
nesiritide as a 0.01-µg/kg/min infusion for 48 hours
versus
placebo
acute decompensated heart failure with moderate to severe renal insufficiency Double blind
Follow-up duration: 7 days
US
FUSION 2, 2008
NCT00091520
nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours)
versus
placebo
patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/mindouble-blind
Follow-up duration: 12 weeks
NSGET (efficacy trial), 2000
nesiritide(0.015 and 0.030 microg/kg/min
versus
placebo
acutely decompensated heart failure requiring invasive monitoring
PROACTION, 2003
nesiritidefor at least 12h
versus
placebo
patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activitydouble-blind
Follow-up duration: 30 days
USA
VMAC (intravenous neseritide), 2002
NCT00083772
intravenous nesiritidefor 3 hours
versus
placebo
acutely decompensated heart failure requiring hospitalization double-blind
USA
nesiritide versus standard care
FUSION 1, 2004
NCT00270361
nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly
versus
standard care
outpatient with co-morbid advanced heart failure and renal insufficiency open
Follow-up duration: 12 weeks
rolofylline versus placebo
PROTECT, 2010
NCT00328692
daily intravenous rolofylline (30 mg) for up to 3 days
versus
placebo
patients hospitalized for acute heart failure with impaired renal functiondouble-blind
Follow-up duration: 3 days (60 days)
serelaxin versus placebo
Pre-RELAX-AHF, 2009
NCT00520806
intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily
versus
placebo
Patients hospitalized with acute heart failure double blind
RELAX-AHF, 2013
NCT00520806
48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation
versus
placebo (on top stnadard care)
patients admitted to hospital for acute heart failure

  Options


in first

in second

  Filter